

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1-80 (canceled)

81. (Currently amended): A method for detecting a gestational trophoblast malignancy in a subject who is either pregnant or suspected of being pregnant, comprising the steps of:

(a)(i) contacting a first portion of a urine sample from the subject with an antibody which binds to EPMI-hCG under conditions permitting the formation of a complex between the antibody and any EPMI-hCG present in the sample, wherein the antibody distinguishes between C5 chorio hCG and CR127 hCG, and has an association constant which is about an order of magnitude greater with respect to C5 chorio hCG than with respect to CR127 hCG; and

(ii) measuring the amount of any complex formed, so as to thereby determine the amount of EPMI-hCG in the sample;

(b)(i) contacting a second portion of the urine sample from the subject with an antibody which binds to intact hCG under conditions permitting the formation of a complex between the antibody and any intact hCG present in the sample; and

(ii) measuring the amount of any complex formed, so as to thereby determine the amount of intact hCG in the sample, with the proviso that steps (a) and (b) can be performed in any order;

- Sub
P1
- (c) determining the ratio of EPMI-hCG to intact hCG in the sample from the measurements performed in (a)(ii) and (b)(ii); and
 - (d) repeating steps (a) through (c) at least once over a suitable time period, wherein a ratio of EPMI-hCG to intact hCG greater than 1.0 occurring over such time period indicates the presence of a gestational trophoblast malignancy.

82. (Currently amended): A method for detecting a gestational trophoblast malignancy in a subject who is either pregnant or suspected of being pregnant, comprising the steps of:

- G5
- (a)(i) contacting a first portion of a urine sample from the subject with a first antibody which binds to EPMI-hCG under conditions permitting the binding of the first antibody with any EPMI-hCG present in the sample, wherein the antibody distinguishes between C5 chorio hCG and CR127 hCG, and has an association constant which is about an order of magnitude greater with respect to C5 chorio hCG than with respect to CR127 hCG, and wherein the first antibody is bound to a solid support;
 - (ii) removing any unbound sample from the solid support;
 - (iii) contacting the solid support with a second antibody which binds to bound EPMI-hCG under conditions permitting the binding of the second antibody to bound EPMI-hCG; and
 - (iv) measuring the amount of the second antibody bound to the bound EPMI-hCG, so as to thereby determine the amount of EPMI-hCG in the sample;
 - (b)(i) contacting a second portion of the urine sample with a third antibody which binds to intact hCG under conditions permitting the binding of the

Sub
FI

third antibody with any intact hCG present in the sample, wherein the third antibody is bound to a solid support;

(ii) removing any unbound sample from the solid support;

(iii) contacting the solid support with a fourth antibody which binds to bound intact hCG under conditions permitting the binding of the fourth antibody to bound intact hCG; and

(iv) measuring the amount of the fourth antibody bound to the bound intact hCG, so as to thereby determine the amount of intact hCG in the sample, with the proviso that steps (a) and (b) can be performed in any order;

(c) determining the ratio of EPMI-hCG to intact hCG in the sample from the measurements performed in (a)(iv) and (b)(iv); and

GS

(d) repeating steps (a) through (c) at least once over a suitable time period, wherein a ratio of EPMI-hCG to intact hCG greater than 1.0 occurring over such time period indicates the presence of a gestational trophoblast malignancy.

83. (Currently amended): The method of claim 81 or 82, wherein the antibody which binds to EPMI-hCG is B152, produced by the hybridoma deposited with the American Type Culture Collection under Designation No. HB-12467.

84. (Currently amended): The method of claim 81 or 82, wherein the antibody which binds to intact hCG is B109, produced by the hybridoma deposited with the American Type Culture Collection under Designation No. PTA-1624.

Sub
FI

85. (Currently amended): The method of claim 82, wherein the second antibody is B207, produced by the hybridoma deposited

Applicants: John Connor et al.

Serial No.: 09/311,428

Filed: May 13, 1999

Page 11

Sub
FI
with the American Type Culture Collection under Designation
No. PTA-1626.

86. (Currently amended): The method of claim 82, wherein the
fourth antibody is B108, produced by the hybridoma deposited
with the American Type Culture Collection under Designation
No. PTA-1625.

87. (previously presented): The method of claim 81 or 82, wherein
the gestational trophoblast malignancy is a hydatidiform
mole.

88. (previously presented): The method of claim 81 or 82, wherein
the gestational trophoblast malignancy is a choriocarcinoma.

89. (previously presented): The method of claim 82, wherein the
second and fourth antibodies are each labeled with a
detectable marker.

90. (previously presented): The method of claim 89, wherein the
detectable marker is a radioactive isotope, enzyme, dye,
magnetic bead, or biotin.

91. (previously presented): The method of claim 90, wherein the
detectable marker is a radioactive isotope, and the
radioactive isotope is I¹²⁵.
